Hospital- and clinic-based smoking cessation interventions for smokers with cardiovascular disease

Prog Cardiovasc Dis. 2003 May-Jun;45(6):459-79. doi: 10.1053/pcad.2003.YPCAD15.


Cigarette smoking is the leading preventable cause of death in the United States and a major risk factor for cardiovascular disease (CVD). Large observational epidemiologic studies conducted in diverse populations have demonstrated a strong association between smoking and CVD morbidity and mortality. Observational epidemiologic studies have also demonstrated a substantial benefit of smoking cessation on cardiovascular morbidity and mortality. Smoking cessation after myocardial infarction reduces subsequent cardiovascular mortality by nearly 50%. Therefore, the use of effective strategies to reduce the prevalence of tobacco use is a high priority for both the primary and secondary prevention of CVD. Effective smoking cessation interventions have been identified in randomized controlled trials in the general population of smokers. These methods, which include behavioral counseling and pharmacotherapy, are incorporated into clinical practice guidelines for physicians in the United States and Great Britain. A smaller but still substantial body of evidence demonstrates the efficacy of these interventions in hospital- and clinic-based settings for smokers with CVD. This evidence is sufficient to support the routine implementation of these smoking cessation methods in inpatient and outpatient settings for smokers with CVD.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Ambulatory Care
  • Behavior Therapy
  • Bupropion / adverse effects
  • Bupropion / therapeutic use
  • Cardiovascular Diseases*
  • Clinical Trials as Topic
  • Hospitalization
  • Humans
  • Nicotine / administration & dosage
  • Nicotine / adverse effects
  • Nicotine / therapeutic use
  • Practice Guidelines as Topic
  • Smoking Cessation*


  • Bupropion
  • Nicotine